The Shotlee Journal
Browse Shotlee articles about Mounjaro.
Showing 9 / 799 Mounjaro articles
Popular GLP-1 medications, known for their weight loss efficacy, are now showing potential to combat arthritis inflammation. Discover what this groundbreaking research means for joint health.
Concerns are mounting over the integrity of the pharmaceutical supply chain as the FDA takes action against a Chinese supplier for questionable practices involving critical GLP-1 drug ingredients. This development raises questions about the safety and reliability of active pharmaceutical ingredients used in popular weight loss and diabetes medications.
The launch of GLP-1 agonists like Ozempic and Wegovy has not only transformed weight management but also sparked an unexpected trend: a significant increase in vitamin supplement sales. This article delves into the potential reasons behind this phenomenon and what it signifies for individuals managing their health with these powerful medications.
Two generic versions of Ozempic have arrived in Canadian pharmacies, offering diabetes and weight loss patients significant cost savings compared to the brand-name medication.
Eli Lilly's Retatrutide has shown remarkable weight loss potential in Phase 3 trials. We break down the TRIUMPH-1 results, safety data, and what patients can expect.
New regulations warn that GLP-1 medication users could face significant fines if side effects impair driving. Here is the complete guide to staying safe and compliant.
Clinical trials for the triple-agonist Retatrutide show promising weight loss, but 11% of high-dose participants dropped out due to side effects.
Many women starting GLP-1 therapies experience significant weight loss, only to find their menopausal symptoms—like hot flashes and sleep issues—intensify. This phenomenon is often overlooked because rapid fat loss directly interacts with the body's declining estrogen production, creating a complex hormonal shift that many prescribers are not trained to address.
Eli Lilly's retatrutide is making waves in the weight loss landscape. This comprehensive look delves into its Phase III results, comparing it to existing treatments and exploring its potential impact on obesity management.
